Size of the exposed body surface area, skin erythema and body mass index predict skin production of vitamin D.

J Photochem Photobiol B

Dept of Dermatology, Sahlgrenska University Hospital at Sahlgrenska Academy, University of Gothenburg, Sweden; Dept of Dermatology, RH University Hospital, Norway.

Published: August 2015

Background: Cholecalciferol (vitamin D3), produced in the skin by UVB irradiation (290-315nm) of 7-dehydrocholesterol, is metabolized in the liver into 25-hydroxyvitamin D [25(OH)D] which is a major circulating metabolite.

Aim: To examine changes in serum concentrations of cholecalciferol and its metabolites after UVB exposure of different skin areas.

Methods: 21 healthy Caucasians (skin type II and III, aged 23-47years) were exposed to broadband UVB (290-320nm) and randomized to either exposure to one minimal erythema dose given as a single dose, or a suberythemic dose given for 3 subsequent days. The following areas were exposed: face and back of hands, upper half of the body and the whole body, respectively. Serum cholecalciferol and 25(OH)D were measured immediately before start and 24h after the 1st and last exposure, respectively.

Results: Subjects with whole body exposure had an average S-cholecalciferol increase per dose unit of 0.18ngml(-1)mJ(-1)cm(2), 0.95 CI: (0.16, 0.20), upper body treatment 0.13ngml(-1)mJ(-1)cm(2), 0.95 CI: (0.10, 0.15) and face and hands exposure 0.013ngml(-1)mJ(-1)cm(2), 0.95 CI: (-0.012, 0.037). The increase in cholecalciferol correlated positively to the UVB dose and skin erythema and negatively to body mass index (BMI) when controlling for other factors. Exposure of face and hands induces smaller cholecalciferol production in comparison with exposure of larger skin areas.

Conclusion: Size of the exposed skin area, UVB dose, skin erythema and BMI were the major determinants for serum levels of skin synthesized cholecalciferol. Exposure of hands and face induces smaller cholecalciferol production in comparison with exposure of larger skin areas.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jphotobiol.2015.06.008DOI Listing

Publication Analysis

Top Keywords

skin erythema
12
face hands
12
skin
11
exposure
9
size exposed
8
body mass
8
uvb dose
8
dose skin
8
induces smaller
8
smaller cholecalciferol
8

Similar Publications

Evaluation of the Effectiveness of Using LED Light Combined With Chromophore Gel in Treating Acne Vulgaris - Preliminary Study.

Clin Cosmet Investig Dermatol

January 2025

Department of Basic Biomedical Science, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Sosnowiec, Poland.

Purpose: The aim was to quantitatively evaluate the effectiveness of LED light therapy combined with photoacceptor substances having anti-acne properties in reducing the symptoms of acne vulgaris.

Patients And Methods: 15 subjects aged 20 to 24 who suffered from moderate or severe acne lesions. The treatments were performed using a LED device (465-880 nm).

View Article and Find Full Text PDF

Lyme neuroborreliosis can present with isolated neurological manifestations, posing diagnostic challenges, especially in the absence of hallmark dermatological symptoms like erythema migrans. This case highlights a patient with isolated cervical radiculopathy due to Lyme neuroborreliosis, presenting without systemic features such as fever, arthralgia, or rash. The diagnosis was confirmed through serological testing, with positive findings on the Western blot.

View Article and Find Full Text PDF

Amoxicillin is commonly used to treat erythema migrans in the first stage of Lyme disease in children, with a recommended dose of 50 mg/kg/day, administered three times a day (q8h). This model-based simulation study aimed to determine whether splitting the same daily dose into two administrations (q12h) would provide comparable drug exposure. A pharmacokinetic model suitable for a pediatric population (age: 1 month to 18 years, weight: 4-80 kg) was selected through a literature review.

View Article and Find Full Text PDF

Efficacy and safety of PCSK9 inhibitors in real life.

Clin Investig Arterioscler

January 2025

Unidad de Lípidos y Riesgo Vascular, Servicio de Endocrinología y Nutrición, Hospital del Mar, Barcelona, España. Electronic address:

Objective: To confirm the effectiveness and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in daily clinical practice.

Methods: Retrospective observational study of patients from hospital registry of PCSK9 inhibitor treatment with a follow-up ≥ 6 months. The lipid-lowering effect and safety were evaluated.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!